{"disease":{"id":"sma","name":"sma"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"osimertinib","indication_name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"ravulizumab","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"durvalumab","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"durvalumab","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imfinzi","generic_name":"durvalumab","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":"4900","mechanism":"Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"atezolizumab","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"atezolizumab","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecentriq","generic_name":"atezolizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"3700","mechanism":"Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system."},{"drug_id":"ibrutinib","indication_name":"M  lymphoplasmacytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"ibrutinib","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"acalabrutinib","indication_name":"Chronic lymphocyticleukemia/small lymphocytic lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calquence","generic_name":"ACALABRUTINIB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase BTK","drug_class":"Kinase Inhibitor [EPC]","quality_score":59,"revenue":"3100","mechanism":"Calquence works by blocking the activity of the BTK enzyme, which is essential for the activation and survival of B cells."},{"drug_id":"ipilimumab","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"venetoclax","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venclexta","generic_name":"venetoclax","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"BCL-2 Inhibitor [EPC]","quality_score":80,"revenue":"2583","mechanism":"Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein."},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"bevacizumab","indication_name":"Nonsquamous nonsmall cell neoplasm of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"bevacizumab","indication_name":"Non-small cell lung cancer with mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"nintedanib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"cemiplimab","indication_name":"Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"cemiplimab","indication_name":"Non-small cell lung cancer without mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"immuno-oncology-io","indication_name":"Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"lorbrena","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"Lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"1100","mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."},{"drug_id":"lorbrena","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"Lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"1100","mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."},{"drug_id":"ramucirumab","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"amivantamab","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rybrevant","generic_name":"AMIVANTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"EGFR, MET","drug_class":"","quality_score":59,"revenue":"800","mechanism":"Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells."},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) with brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"selpercatinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"alectinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alecensa","generic_name":"alectinib","company_name":"Hoffmann-La Roche","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor","quality_score":79,"revenue":"700","mechanism":"Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"selpercatinib","indication_name":"Advanced RET fusion-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retevmo","generic_name":"SELPERCATINIB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":69,"revenue":"700","mechanism":"Retevmo works by blocking the activity of the RET protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"afatinib","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gilotrif","generic_name":"afatinib","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":68,"revenue":"400","mechanism":"Gilotrif works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow."},{"drug_id":"tremelimumab","indication_name":"Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imjudo","generic_name":"TREMELIMUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"CTLA-4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":62,"revenue":"400","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth."},{"drug_id":"tremelimumab","indication_name":"Non-small cell lung cancer, negative for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imjudo","generic_name":"TREMELIMUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"CTLA-4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":62,"revenue":"400","mechanism":"Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth."},{"drug_id":"azithromycin","indication_name":"Pelvic inflammatory disease due to Mycoplasma hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zithromax","generic_name":"azithromycin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor","drug_class":"Macrolide antibiotic (azalide)","quality_score":67,"revenue":"399","mechanism":"Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life."},{"drug_id":"azithromycin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zithromax","generic_name":"azithromycin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor","drug_class":"Macrolide antibiotic (azalide)","quality_score":67,"revenue":"399","mechanism":"Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life."},{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"nabpaclitaxel","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"paclitaxel","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nab-paclitaxel","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"sotorasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumakras","generic_name":"SOTORASIB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":65,"revenue":"300","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth."},{"drug_id":"entrectinib","indication_name":"Reactive oxygen species 1 positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rozlytrek","generic_name":"entrectinib","company_name":"Roche","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"","quality_score":59,"revenue":"300","mechanism":"Rozlytrek works by blocking the activity of a specific protein called the nerve growth factor receptor."},{"drug_id":"adagrasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krazati","generic_name":"ADAGRASIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":66,"revenue":"205","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth."},{"drug_id":"repotrectinib","indication_name":"Locally advanced or metastatic ROS1-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"capmatinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tabrecta","generic_name":"CAPMATINIB","company_name":"Novartis Pharm","drug_phase":"marketed","molecular_target":"Hepatocyte growth factor receptor","drug_class":"Kinase Inhibitor","quality_score":66,"revenue":"200","mechanism":"Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread."},{"drug_id":"oxaliplatin","indication_name":"Small intestine cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eloxatin","generic_name":"Oxaliplatin","company_name":"Yakult Honsha","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Platinum-based chemotherapy agent","quality_score":70,"revenue":null,"mechanism":"Oxaliplatin forms platinum-DNA crosslinks that inhibit replication and transcription."},{"drug_id":"gemcitabine-hydrochloride","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"Gemcitabine Hydrochloride","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase; DNA incorporation","drug_class":"Nucleoside metabolic inhibitor","quality_score":69,"revenue":null,"mechanism":"Gemcitabine kills cells during DNA synthesis and blocks G1/S-phase progression."},{"drug_id":"fluocinolone-acetonide","indication_name":"Chloasma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dronedarone","indication_name":"Paroxysmal atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Multaq","generic_name":"DRONEDARONE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily KQT member 2","drug_class":"Antiarrhythmic [EPC]","quality_score":10,"revenue":null,"mechanism":"Multaq works by blocking abnormal electrical signals in the heart to restore a normal heartbeat."},{"drug_id":"moxifloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"gemifloxacin-mesylate","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Factive","generic_name":"GEMIFLOXACIN MESYLATE","company_name":"Lg Chem Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"Quinolone Antimicrobial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"gemifloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Factive","generic_name":"GEMIFLOXACIN","company_name":"Lg Chem Ltd","drug_phase":"marketed","molecular_target":"","drug_class":"Quinolone Antimicrobial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"mobocertinib","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exkivity","generic_name":"MOBOCERTINIB","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-4","drug_class":"Kinase Inhibitor","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"adenosine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenocard","generic_name":"ADENOSINE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"Adenosine Receptor Agonist [EPC]","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"necitumumab","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Portrazza","generic_name":"NECITUMUMAB","company_name":"Eli Lilly Co","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Portrazza works by blocking the epidermal growth factor receptor (EGFR) protein, which is involved in cancer cell growth and proliferation."},{"drug_id":"necitumumab","indication_name":"Squamous non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Portrazza","generic_name":"NECITUMUMAB","company_name":"Eli Lilly Co","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Portrazza works by blocking the epidermal growth factor receptor (EGFR) protein, which is involved in cancer cell growth and proliferation."},{"drug_id":"crovalimab","indication_name":"paroxysmal nocturnal hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piasky","generic_name":"CROVALIMAB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Complement C5 Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Piasky works by blocking the action of the Complement C5 protein, which is involved in the immune system's response to foreign substances."},{"drug_id":"flecainide","indication_name":"Paroxysmal atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Paroxysmal atrial flutter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"telisotuzumab","indication_name":"non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"pemetrexed","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alimta","generic_name":"pemetrexed","company_name":"Actavis","drug_phase":"marketed","molecular_target":"Folate receptor alpha","drug_class":"Folate Analog Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Alimta works by inhibiting the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell division."},{"drug_id":"hematoporphyrin","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Photodyn","generic_name":"Hematoporphyrin","company_name":"Hepatopancreatobiliary Surgery Institute of Gansu Province","drug_phase":"phase_1","molecular_target":"","drug_class":"hematoporphyrin","quality_score":null,"revenue":null,"mechanism":"Photodyn works by being activated by light, which then kills cancer cells through a process called photodynamic therapy."},{"drug_id":"zirabev","indication_name":"Non-small cell lung cancer with mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"zirabev","indication_name":"Nonsquamous nonsmall cell neoplasm of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"vinorelbin","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vinorelbin","company_name":"National Cancer Institute, Slovakia","drug_phase":"discontinued","molecular_target":"Substance-K receptor, Cytochrome P450 3A4, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"erythromycin","indication_name":"Erythrasma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"E-Mycin","generic_name":"erythromycin","company_name":"Generic (originally Abbott/Lilly)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1","drug_class":"Macrolide [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"erythromycin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"E-Mycin","generic_name":"erythromycin","company_name":"Generic (originally Abbott/Lilly)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1","drug_class":"Macrolide [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"topotecan","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nogitecan","generic_name":"topotecan","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"topotecan","quality_score":80,"revenue":null,"mechanism":"Topotecan is a topoisomerase inhibitor that prevents DNA re-ligation, causing double-strand DNA damage."},{"drug_id":"allr3","indication_name":"Relapsed or refractory small lymphocytic lymphoma (SLL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"lorlatinib","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."},{"drug_id":"lorlatinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."},{"drug_id":"tagraxofusp","indication_name":"Blastic plasmacytoid dendritic cell neoplasm","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Molecule 129","generic_name":"TAGRAXOFUSP","company_name":"Stemline Therapeeutics Inc","drug_phase":"marketed","molecular_target":"Elongation factor 2","drug_class":"CD123 Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Tagraxofusp works by binding to CD123 on cancer cells, causing them to die."},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of repetitive paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"pf-06823859","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50%) as monotherapy (pembrolizumab in combination with pemetrexed and platinum (pemetrexed + platinum) in patients with a PD-L1 TPS ≥ 1% as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06804103","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06804103","generic_name":"pf-06804103","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"EGFR Exon 20 Insertion Mutations","drug_class":"not specified","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with an activating EGFR mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic non-small cell lung cancer with a tumor harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"alatrofloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"navelbine","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Navelbine","company_name":"University of California, San Francisco","drug_phase":"discontinued","molecular_target":"Substance-K receptor, Cytochrome P450 3A4, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the small intestine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-06882961","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06882961","generic_name":"pf-06882961","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":10,"revenue":null,"mechanism":"Not specified"},{"drug_id":"folfiri","indication_name":"Treatment of colorectal cancer that has spread to the liver and the small intestine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1, or SMA type 2 or 3 in patients with a body weight of 13 kg or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tretinoin","indication_name":"Chloasma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retin-A","generic_name":"TRETINOIN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-beta","drug_class":"Retinoid [EPC]","quality_score":58,"revenue":null,"mechanism":"Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation."},{"drug_id":"pembrolizuma","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"eculizumab","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"hydroxydaunorubicin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hycamtin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hycamtin","company_name":"North Eastern German Society of Gynaecological Oncology","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 4, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tagrisso","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tagrisso","company_name":"Suzhou Genhouse Bio Co., Ltd.","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Cysteine--tRNA ligase, cytoplasmic, Dipeptidyl peptidase 1","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"avelox","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"hydroquinone","indication_name":"Chloasma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tri-Luma","generic_name":"HYDROQUINONE","company_name":"Galderma Labs Lp","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Melanin Synthesis Inhibitor [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"taxotere","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxotere","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"yervoy","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Extensive stage primary small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"imfinzi","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imfinzi","company_name":"University Medical Center Groningen","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"amivantamab-vmjw","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYBREVANT","generic_name":"AMIVANTAMAB-VMJW","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor, Hepatocyte growth factor receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"tremelimumab-actl","indication_name":"Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IMJUDO","generic_name":"TREMELIMUMAB-ACTL","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"tremelimumab-actl","indication_name":"Non-small cell lung cancer, negative for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IMJUDO","generic_name":"TREMELIMUMAB-ACTL","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"dioxybenzone","indication_name":"Chloasma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dioxybenzon","generic_name":"DIOXYBENZONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"dacomitinib-hydrate","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitinib hydrate","generic_name":"dacomitinib-hydrate","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho","quality_score":null,"revenue":null,"mechanism":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho"},{"drug_id":"dacomitinib-hydrate","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitinib hydrate","generic_name":"dacomitinib-hydrate","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho","quality_score":null,"revenue":null,"mechanism":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho"},{"drug_id":"metahexamide","indication_name":"Chloasma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Melanex","generic_name":"METAHEXAMIDE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"metahexamide","quality_score":null,"revenue":null,"mechanism":"Melanex works by inhibiting the enzyme tyrosinase, which is involved in the production of melanin, the pigment responsible for skin color."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"diltiazem","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardizem","generic_name":"diltiazem","company_name":"Generic (originally Tanabe Seiyaku)","drug_phase":"marketed","molecular_target":"Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1","drug_class":"Calcium channel blocker (non-dihydropyridine, benzothiazepine)","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"lefamulin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xenleta","generic_name":"LEFAMULIN","company_name":"Hong Kong","drug_phase":"marketed","molecular_target":"","drug_class":"Pleuromutilin Antibacterial","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"imbruvica","indication_name":"M  lymphoplasmacytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imbruvica","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"calquence","indication_name":"Chronic lymphocyticleukemia/small lymphocytic lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calquence","company_name":"iOMEDICO AG","drug_phase":"marketed","molecular_target":"Platelet glycoprotein VI, Cytoplasmic tyrosine-protein kinase BMX, Tyrosine-protein kinase Blk","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"docetaxol","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Docetaxol","company_name":"Fudan University","drug_phase":"phase_2","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofev","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"gatifloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zymar","generic_name":"GATIFLOXACIN","company_name":"Allergan","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"vizimpro","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"Dacomitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor","quality_score":75,"revenue":null,"mechanism":"Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations."},{"drug_id":"vizimpro","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"Dacomitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor","quality_score":75,"revenue":null,"mechanism":"Irreversible pan-HER kinase inhibitor targeting EGFR, HER2, HER4, and EGFR-activating mutations."},{"drug_id":"gemcitabine","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gemzar","generic_name":"gemcitabine","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"DNA polymerase (alpha/delta/epsilon)","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":75,"revenue":null,"mechanism":"Gemzar works by mimicking a building block of DNA, tricking cancer cells into incorporating it into their DNA and then stopping the replication process."},{"drug_id":"grepafloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tomefloxacin","generic_name":"GREPAFLOXACIN","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"grepafloxacin","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"fluorouracil","indication_name":"Small intestine cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"glucarpidase","indication_name":"Toxic plasma methotrexate concentration reduction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voraxaze","generic_name":"GLUCARPIDASE","company_name":"Btg International Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Carboxypeptidase [EPC]","quality_score":60,"revenue":null,"mechanism":"Voraxaze works by breaking down the chemotherapy medication methotrexate into a less toxic form."},{"drug_id":"erythrocin","indication_name":"Erythrasma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"Erythromycin Lactobionate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"erythrocin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"Erythromycin Lactobionate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"gefitinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iressa","generic_name":"gefitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Iressa blocks the epidermal growth factor receptor (EGFR) signaling pathway, preventing cancer cell growth and proliferation."},{"drug_id":"gefitinib","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iressa","generic_name":"gefitinib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Iressa blocks the epidermal growth factor receptor (EGFR) signaling pathway, preventing cancer cell growth and proliferation."},{"drug_id":"crizotinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xalkori","generic_name":"crizotinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Hepatocyte growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Xalkori works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread."},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06835375","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as determined by an FDA-approved test in patients whose tumors have progressed during or following platinum-containing therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06835375","generic_name":"pf-06835375","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Immunotherapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"zanubrutinib","indication_name":"Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"ZANUBRUTINIB","company_name":"BeiGene","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"lurbinectedin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepzelca","generic_name":"LURBINECTEDIN","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Zepzelca works by attaching an alkyl group to DNA, which interferes with DNA replication and causes cell death."},{"drug_id":"erlotinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tarceva","generic_name":"erlotinib","company_name":"Osi Pharms","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Tarceva works by blocking the epidermal growth factor receptor, a protein that helps cancer cells grow."},{"drug_id":"xalkori","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xalkori","generic_name":"Crizotinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Hepatocyte growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Xalkori works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread."},{"drug_id":"porfimer","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Photofrin","generic_name":"porfimer","company_name":"Concordia Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Photoactivated Radical Generator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"taletrectinib","indication_name":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibtrozi","generic_name":"TALETRECTINIB","company_name":"Nuvation","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells."},{"drug_id":"liposomal-doxorubicin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-06882961-cohort-3","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohort 3)","generic_name":"pf-06882961-cohort-3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"anti-ox40-antibody-pf-04518600","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anti-OX40 Antibody PF-04518600","generic_name":"anti-ox40-antibody-pf-04518600","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"OX40 receptor","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"sparfloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sparcin","generic_name":"SPARFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"telithromycin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ketek","generic_name":"TELITHROMYCIN","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Ketolide Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"vinorelbine","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Navelbine","generic_name":"vinorelbine","company_name":"Pierre Fabre","drug_phase":"marketed","molecular_target":"Substance-K receptor","drug_class":"Vinca Alkaloid","quality_score":76,"revenue":null,"mechanism":"Navelbine works by binding to the Substance-K receptor, disrupting microtubule formation and inhibiting cell division."},{"drug_id":"dacomitinib","indication_name":"EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"dacomitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive."},{"drug_id":"dacomitinib","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vizimpro","generic_name":"dacomitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vizimpro works by blocking the EGFR tyrosine kinase, a protein that helps cancer cells grow and survive."},{"drug_id":"trametinib","indication_name":"Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"docetaxel","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxotere","generic_name":"Docetaxel","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Microtubule Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division."},{"drug_id":"pralsetinib","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gavreto","generic_name":"PRALSETINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"RET","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth."},{"drug_id":"pralsetinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gavreto","generic_name":"PRALSETINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"RET","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Pralsetinib inhibits RET kinase and its oncogenic fusions/mutations, blocking downstream signaling and reducing tumor growth."},{"drug_id":"norfloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"levofolinic-acid","indication_name":"Small intestine cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"Levofolinic acid","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"levoleucovorin","indication_name":"Small intestine cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fusilev","generic_name":"levoleucovorin","company_name":"Acrotech Biopharma","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog","quality_score":65,"revenue":null,"mechanism":"Fusilev works by bypassing the enzyme dihydrofolate reductase, allowing normal cell growth and DNA synthesis."},{"drug_id":"iptacopan","indication_name":"Paroxysmal Nocturnal Hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabhalta","generic_name":"IPTACOPAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Factor B","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G."},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults and in combination with pembrolizumab in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"dirithromycin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dirythromycin","generic_name":"DIRITHROMYCIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"dirithromycin","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"methoxamine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methoxamin","generic_name":"METHOXAMINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"methoxamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"minocycline","indication_name":"Ureaplasma Urealyticum Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"doxorubicin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"lorviqua","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"},{"drug_id":"lorviqua","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"},{"drug_id":"clarithromycin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biaxin","generic_name":"clarithromycin","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Clarithromycin is a macrolide antimicrobial drug."},{"drug_id":"doxycycline","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"carbamide","indication_name":"Metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"(CARBAMIDE®)","company_name":"German University in Cairo","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinase-like 5, Hepatocyte growth factor receptor","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"duvelisib","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Copiktra","generic_name":"DUVELISIB","company_name":"Secura","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Copiktra works by blocking an enzyme that helps cancer cells grow and multiply."},{"drug_id":"levofloxacin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"ravulizumab-cwvz","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ultomiris","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pemetrexe","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pemetrexe","company_name":"Rongjie Tao","drug_phase":"marketed","molecular_target":"Serine hydroxymethyltransferase, cytosolic, Folate receptor beta, Folate transporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adenosin","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adenosin","company_name":"University of Roma La Sapienza","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gilotrif","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gilotrif","company_name":"Seoul St. Mary's Hospital","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Adenosine kinase, Casein kinase I isoform epsilon","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"abraxane","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vargatef","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ofloxacine","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pluvicto","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pluvicto","company_name":"VA Office of Research and Development","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"","quality_score":11,"revenue":null,"mechanism":null},{"drug_id":"tarceva","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tarceva","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"AarF domain-containing protein kinase 4, Acyl-CoA dehydrogenase family member 11, Chaperone activity of bc1 complex-like, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"etoposid","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Etoposid","company_name":"University of Ulm","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"soliris","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zepzelca","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zepzelca","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zydelig","indication_name":"Malignant lymphoma - small lymphocytic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zydelig","company_name":"University of Maryland, Baltimore","drug_phase":"marketed","molecular_target":"DNA-dependent protein kinase catalytic subunit, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"minocyclin","indication_name":"Ureaplasma Urealyticum Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"photofrin","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Photofrin","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"met097","indication_name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Met097","generic_name":"met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"bevacizumab-maly","indication_name":"Non-Squamous Non-Small Cell Lung Cancer - First Line","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"sodium-citrate","indication_name":"Platelet Rich Plasma (PRP) preparation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bss","generic_name":"SODIUM CITRATE","company_name":"B Braun","drug_phase":"marketed","molecular_target":"Calcium","drug_class":"sodium citrate","quality_score":51,"revenue":null,"mechanism":"ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A prevents blood clotting by binding free calcium, a crucial co-factor in the clotting cascade."},{"drug_id":"flecainide","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"tagraxofusp","indication_name":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Molecule 129","generic_name":"TAGRAXOFUSP","company_name":"Stemline Therapeeutics Inc","drug_phase":"marketed","molecular_target":"Elongation factor 2","drug_class":"CD123 Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Tagraxofusp works by binding to CD123 on cancer cells, causing them to die."},{"drug_id":"flecainide","indication_name":"Paroxysmal Atrial Fibrillation/Flutter (PAF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"eculizumab-aeeb","indication_name":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"onasemnogene-abeparvovec-brve","indication_name":"Spinal Muscular Atrophy (SMA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Onasemnogene Abeparvovec-brve","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"SMN1 gene","drug_class":"Gene Therapy","quality_score":10,"revenue":null,"mechanism":"ITVISMA delivers a functional SMN1 gene using an AAV9 vector to promote SMN protein expression in motor neurons."},{"drug_id":"dostarlimab-gxly","indication_name":"Mismatch Repair Deficient Recurrent or Advanced Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"tecovirimat-monohydrate","indication_name":"Treatment of Human Smallpox Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TECOVIRIMAT MONOHYDRATE","company_name":"","drug_phase":"marketed","molecular_target":"variola (smallpox) virus","drug_class":"Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor [EPC]","quality_score":49,"revenue":null,"mechanism":"Tecovirimat is an antiviral drug that targets the variola (smallpox) virus."},{"drug_id":"chembl-chembl1789844","indication_name":"Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Metastatic Non-Small Cell Lung Cancer (PD-L1 ≥1%)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Metastatic or Recurrent Non-Small Cell Lung Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl44657","indication_name":"Small Cell Lung Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ETOPOSIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"lutetium-lu-177-vipivotide-tetraxetan","indication_name":"PSMA-positive mCRPC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN","company_name":"","drug_phase":"marketed","molecular_target":"PSMA","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":"Lutetium Lu 177 vipivotide tetraxetan binds to PSMA on prostate cancer cells, delivering radiation that causes DNA damage and cell death."},{"drug_id":"flecainide-acetate","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"flecainide-acetate","indication_name":"Paroxysmal Atrial Fibrillation/Flutter (PAF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"doxycycline","indication_name":"Respiratory tract infections caused by Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-in-combination-with-docetaxel","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 in combination with docetaxel","generic_name":"pf-06939999-in-combination-with-docetaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein kinase","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"doxycyclin","indication_name":"Pneumonia due to Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"brigatinib","indication_name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."},{"drug_id":"brigatinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."},{"drug_id":"5-fu","indication_name":"Small intestine cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"icotinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ICOTINIB","company_name":"Zhejiang Beta Pharma Inc.","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"brincidofovir","indication_name":"human smallpox disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tembexa","generic_name":"BRINCIDOFOVIR","company_name":"Emergent Biodefense","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Tembexa works by inhibiting the replication of viruses."},{"drug_id":"brincidofovir","indication_name":"diseases other than human smallpox disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tembexa","generic_name":"BRINCIDOFOVIR","company_name":"Emergent Biodefense","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Tembexa works by inhibiting the replication of viruses."},{"drug_id":"gemcitabin","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gemcitabin","company_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","drug_phase":"marketed","molecular_target":"UMP-CMP kinase, Deoxycytidine kinase, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"iressa","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Iressa","company_name":"David Adelstein","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Ferrochelatase, mitochondrial, Mitogen-activated protein kinase 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"iressa","indication_name":"Non-small cell lung cancer, positive for epidermal growth factor receptor expression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Iressa","company_name":"David Adelstein","drug_phase":"discontinued","molecular_target":"Citron Rho-interacting kinase, Ferrochelatase, mitochondrial, Mitogen-activated protein kinase 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"belotecan","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camtobell","generic_name":"BELOTECAN","company_name":"Chong Kun Dang","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1","drug_class":"belotecan","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Non-small cell lung cancer with mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avastin","indication_name":"Nonsquamous nonsmall cell neoplasm of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."},{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."},{"drug_id":"ceritinib","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zykadia","generic_name":"ceritinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zykadia blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"ceritinib","indication_name":"Non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zykadia","generic_name":"ceritinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zykadia blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"etoposide","indication_name":"Small cell carcinoma of lung","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vepesid","generic_name":"etoposide","company_name":"Bristol-Myers Squibb K.K.","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"dacomitnib","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitnib","generic_name":"dacomitnib","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis","quality_score":null,"revenue":null,"mechanism":"patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis"},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Small-cell lung cancer (olaparib + low-dose radiotherapy)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"pf-06439535-cn","indication_name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06439535 (CN)","generic_name":"pf-06439535-cn","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","drug_class":"Selective pathway inhibitor; presumed anti-angiogenic agent","quality_score":null,"revenue":null,"mechanism":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells."},{"drug_id":"sasanlimab-prefilled-syringe","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sasanlimab Prefilled syringe","generic_name":"sasanlimab-prefilled-syringe","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"prefilled syringe","quality_score":0,"revenue":null,"mechanism":"prefilled syringe"},{"drug_id":"sea-tgt","indication_name":"Carcinoma, Non-Small-Cell Lung","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SEA-TGT","generic_name":"sea-tgt","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"solution in vials","quality_score":null,"revenue":null,"mechanism":"solution in vials"},{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."},{"drug_id":"lorviqua","indication_name":"Metastatic ALK+ Non Small Cell Lung Cancer","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"}],"offLabel":[],"totalMarketed":387,"totalPipeline":7},"trials":{"data":[{"nct_id":"NCT05810545","title":"Drinking Water PFAS, Pregnancy Outcome and Maternal Morbidity","phase":"","overall_status":"COMPLETED","enrollment_count":256659,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT00063063","title":"Generic Database of Very Low Birth Weight Infants","phase":"","overall_status":"RECRUITING","enrollment_count":80000,"lead_sponsor_name":"NICHD Neonatal Research Network","has_results":false},{"nct_id":"NCT07052656","title":"Risk Factors and Outcomes in Patients Treated in Neurocritical Care","phase":"","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT00009633","title":"Follow-up Visit of High Risk Infants","phase":"","overall_status":"RECRUITING","enrollment_count":68000,"lead_sponsor_name":"NICHD Neonatal Research Network","has_results":false},{"nct_id":"NCT07036016","title":"Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1","phase":"","overall_status":"COMPLETED","enrollment_count":67818,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06255197","title":"Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03662178","title":"Investigating the Structured Use of Ultrasound Scanning for Fetal Growth","phase":"","overall_status":"RECRUITING","enrollment_count":56000,"lead_sponsor_name":"Oxford University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT03657875","title":"Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network (HEKATE)","phase":"","overall_status":"COMPLETED","enrollment_count":53940,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04137718","title":"Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation","phase":"","overall_status":"UNKNOWN","enrollment_count":50000,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT02623712","title":"The Watch the Spot Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":34686,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT04974138","title":"China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":32000,"lead_sponsor_name":"Shenzhen Ausa Pharmed Co.,Ltd","has_results":false},{"nct_id":"NCT05934032","title":"National Network Genomic Medicine Lung Cancer, Germany","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Prof. Dr. Juergen Wolf","has_results":false},{"nct_id":"NCT06456814","title":"Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT06557967","title":"Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":22517,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03564457","title":"20K Distributed Learning Challenge","phase":"","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT06077305","title":"A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05169021","title":"Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05059951","title":"Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT04088071","title":"Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Heart Rhythm Clinical and Research Solutions, LLC","has_results":false},{"nct_id":"NCT06996249","title":"Prospective Data Collection Initiative on Thoracic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Dutch Society of Physicians for Pulmonology and Tuberculosis","has_results":false},{"nct_id":"NCT03413956","title":"An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":10885,"lead_sponsor_name":"Jiangsu Cancer Institute & Hospital","has_results":false},{"nct_id":"NCT03429673","title":"A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":10885,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05182983","title":"Tongue Image Database and Diagnostic Model for Digestive Tract Disease Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":10690,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT06074601","title":"MIRACLE of LIFE Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Mirvie","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT05257863","title":"Development of Machine Learning Models for the Prediction of Complications After Colonic, Colorectal and Small Intestine Anastomosis in Psychiatric and Non-psychiatric Patient Collectives (P-Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Dr. Med Anas Taha","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT06766422","title":"AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","has_results":false},{"nct_id":"NCT03851445","title":"Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT02964793","title":"Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT07160088","title":"DIND in Patients With aSAH : Real World Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT04962295","title":"China Imaging-based Biobank of Cerebral Small Vessal Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06320223","title":"PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT03153748","title":"New Therapeutic System of Ruptured Intracranial Aneurysms Based on Big Data From Chinese Population","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04056247","title":"Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT03921177","title":"Micronutrient Supplementation Before and During 1st Pregnancy to Improve Birth Outcomes (JiVitA-5)","phase":"NA","overall_status":"TERMINATED","enrollment_count":9859,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT02194738","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05566158","title":"Development and Validation of a CT-based Diagnostic Models Using Artificial Intelligence for Detection of Small Bowel Obstruction","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT03560791","title":"A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence","phase":"","overall_status":"COMPLETED","enrollment_count":7659,"lead_sponsor_name":"St Elizabeth Healthcare","has_results":false},{"nct_id":"NCT02809599","title":"Evidence Based Best Care Practice for Benign Paroxysmal Positional Vertigo","phase":"NA","overall_status":"COMPLETED","enrollment_count":7635,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT00068003","title":"Harvesting Cells for Experimental Cancer Treatments","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06125860","title":"BEP Targeting Strategies in Ethiopia","phase":"NA","overall_status":"RECRUITING","enrollment_count":6750,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":false},{"nct_id":"NCT03505515","title":"Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":6205,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT01374360","title":"Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":6061,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04322890","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT06684418","title":"Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06957769","title":"Biological Impacts of Rising Temperatures on Maternal, Fetal, and Newborn Health: A Cohort Study (BIRTH Cohort)","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT06979856","title":"Short, Animated Storytelling (SAS) Videos to Reduce Smartphone Addiction in the US","phase":"NA","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03115905","title":"A Registry Study for Emergency Medical Service of Aneurysmal Subarachnoid Hemorrhage in China","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}